eli lilly phase 3 trial retatrutide Today, we shared new data from two trials of retatrutide, our investigational triple agonist. Learn more at our link in bio Retatrutide Delivers Bariatric-Level Weight Loss

These findings highlight the potential clinical importance of achieving and maintaining weight loss after GLP-1-based treatment initiation. Meeting: European Congress on Obesity 2026 (ECO2026) Never miss a breakthrough: Join the SciTechDaily newsletter

Details on how the pen itself works are not yet available

Participants transitioning from Zepbound to orforglipron maintained their weight within an average difference of 5.0 kg

For a medication like lamotrigine, consistency is the goal

Patience serves you well during this phase

Weight loss treatments are typically most effective in combination with lifestyle adaptations, including increased physical activity and dietary changes